BenzaClin is the U.S. prescription brand identity for a topical acne gel combining clindamycin 1% (as clindamycin phosphate) with benzoyl peroxide 5%. This two-ingredient formula is not the same as plain clindamycin gel, an OTC benzoyl peroxide product or another fixed combination with different concentrations. For a wider product overview, see the clindamycin/benzoyl peroxide family guide.
The principal manufacturer-linked BenzaClin entries in DailyMed list marketing end dates of February 28, 2022. Those dates describe specific NDC records, not every possible generic gel or independent pharmacy listing. Some BenzaClin packaging required pharmacist reconstitution before dispensing; its preparation, storage and expiration instructions must not be transferred to modern premixed generic products.
This page is a published brand-identity and pharmacy-verification guide, not a promise that BenzaClin-branded stock is currently obtainable. Someone holding a prescription should ask a licensed pharmacy to identify the precise product it can dispense and contact the prescriber if a different formula is proposed. Review the lawful prescription purchase process for the active-ingredient combination.
BenzaClin branded gel contains clindamycin as clindamycin phosphate at 1% and benzoyl peroxide at 5%. Both actives belong in the product identity. An advertisement for benzoyl peroxide alone is not an equivalent prescription purchase, and plain clindamycin gel lacks the second component.
The acne combination hub distinguishes this traditional two-ingredient formula from clindamycin/tretinoin and the newer triple-combination category.
| Element | Historical BenzaClin brand | What requires a new check |
|---|---|---|
| Ingredients | Clindamycin + benzoyl peroxide | Match both components |
| Labeled strengths | 1% / 5% | Do not substitute other ratios blindly |
| Form | Topical prescription gel | Not OTC benzoyl peroxide alone |
| Packaging | Some legacy reconstituted products | Modern marketed presentation |
| Marketing | Archived/inactivated records exist | Currently marketed brand NDC |
| Purchase | Licensed pharmacy and valid Rx | Real current stock and price |
DailyMed identifies BenzaClin manufacturer-linked NDC 0187-5190 presentations as U.S. prescription products, with a marketing end date of February 28, 2022. This is stronger evidence than a generic warning that a listing might be old: it explicitly identifies a discontinued marketing period for the listed branded presentations.
A separate repackager record may still appear in the DailyMed search results. Such a listing does not demonstrate a currently distributed manufacturer-branded package or confirm inventory at an individual pharmacy. Treat each NDC, manufacturer and package as a distinct record, and ask the dispensing pharmacy to confirm its exact product.
The branded product history deserves a useful standalone page because it explains how the 1%/5% formula differs from other acne combinations. Publication of this information does not establish a new BenzaClin launch, current supply or an advertised sale.
The historic BenzaClin label identifies 1% clindamycin and 5% benzoyl peroxide. Other combination gels may use 1.2%/2.5%, 1.2%/3.75% or a 1.2%/5% designation depending on the specific product, so concentration pairs must not be mixed.
For separately branded alternative ratios, compare Acanya and Onexton, then ask the pharmacist how those products differ from the actual prescription.
Some BenzaClin product labeling describes a formulation assembled or reconstituted by the pharmacist before dispensing, with associated storage and beyond-use instructions. These packaging steps are product-specific and should not be copied onto modern premixed generic gels.
If someone has an older box, review its specific package information and expiration date with a pharmacist. An archived mixing instruction is not a safe do-it-yourself preparation method and is not evidence the former package remains available.
Plain clindamycin 1% topical gel has only the antibiotic ingredient, whereas BenzaClin is a two-active-ingredient prescription product. Adding an OTC benzoyl peroxide tube to a plain antibiotic prescription is not automatically the same as using a labeled fixed combination.
The plain gel page addresses single-ingredient products. A patient should follow the dermatologist’s actual treatment plan rather than substituting based on a keyword.
Benzoyl peroxide contributes acne activity while helping reduce the development of antibiotic resistance when used with topical clindamycin. This is part of the evidence-based rationale for combination acne treatment, though suitability depends on the patient and the formulation.
The acne care guide covers antibiotic stewardship. It does not imply that all acne requires this particular historic brand or concentration.
Generic clindamycin/benzoyl peroxide gels have U.S. prescription labeling, including formula families described as 1%/5% and 1.2%/5%, depending on the specific record. A listing for one concentration or generic manufacturer is not evidence that the historic BenzaClin brand package remains in production or that another strength is equivalent.
A pharmacist can check whether a current generic formula meets the prescriber’s order and substitution rules. See generic clindamycin for product identity principles and availability checking for how to confirm current supply.
The fixed antibiotic-containing combination requires a U.S. prescription even though benzoyl peroxide alone may be sold over the counter. An OTC checkout for the second ingredient does not authorize dispensing clindamycin.
For a legitimate prescription transaction involving the combination, see the buy-combination guide. The separate OTC benzoyl peroxide page covers a different product category.
Clindamycin/benzoyl peroxide gels can cause local dryness, redness and irritation. Benzoyl peroxide can bleach fabrics and hair. Product-specific warnings about hypersensitivity, antibiotic-associated colitis and other topical medicines require pharmacist review.
The risk of severe antibiotic-associated diarrhea should not be dismissed completely because the medicine is topical. See the clindamycin adverse-effects page for additional context.
Historical U.S. Duac branding has included a 1.2%/5% formulation, distinct from the BenzaClin 1%/5% branded wording. A generic with 1.2%/5% on the label should not be presented as identical to a different branded strength without regulatory and prescription checks.
Consult the two-ingredient product-family overview for the strengths map; each brand dossier remains limited to its own records.
Archived BenzaClin prices, old coupons and historic package quotes do not establish a meaningful current checkout amount. Ask the pharmacy for a live quote on the exact product it can dispense after any necessary prescriber approval, comparing insurer and cash-pay terms for that product only.
Our topical clindamycin cost guide describes brand/generic and package-size factors without promising savings or naming the cheapest pharmacy.
If the requested brand is not listed at a pharmacy, ask whether the pharmacist can identify a currently marketed clindamycin/benzoyl peroxide product with the prescribed formula and whether a brand-specific substitution is legally and clinically permitted. The prescriber may need to clarify or authorize an alternative; a pharmacist's explanation should not be replaced by a search-result similarity.
Do not order a purported legacy BenzaClin kit from an unverifiable seller or attempt pharmacist reconstitution yourself. Packaging from an old marketing period can be expired, improperly stored or unrelated to the medicine actually prescribed. See online pharmacy verification for checks on licensing and pharmacist access.
The most useful next step is to compare the current prescription with an identified dispensable product, confirm its exact concentrations and route, and request a current pharmacy quote. Generic availability must be confirmed rather than assumed from the existence of an archived brand label.
BenzaClin is a prescription acne-gel brand containing clindamycin 1% and benzoyl peroxide 5%. Its historical manufacturer-linked U.S. package records require distinction from current generics.
DailyMed lists an end date of February 28, 2022 for the principal manufacturer-linked brand NDCs. Other records or sellers do not by themselves confirm current BenzaClin branded inventory; ask a licensed pharmacy.
Yes. The branded formulation contains clindamycin and benzoyl peroxide.
No. Plain clindamycin gel does not contain benzoyl peroxide.
No. A clindamycin-containing fixed combination is a prescription medicine.
No. Match the exact drug product, labeling and prescription with the pharmacist.
Certain older branded presentations required pharmacist reconstitution, which should not be generalized to other gels.
No. A generic listing establishes a different product record.
Ask a licensed pharmacist and prescriber to review current product availability and appropriate alternatives.
No. A current generic drug label and a historical branded NDC are different records. The pharmacy should verify the prescribed product, concentrations and permitted substitution.